The US executive order of 29 September 2026 replaced "artificial intelligence" with "Super Intelligence" in federal writing. Most of the commentary since has been about compliance. The more interesting question for this industry is what, if anything, it changes about how life sciences companies actually build, test, manufacture and sell.
The short version: a great deal of language will change, and very little else. But the language change is not nothing, because of where it lands.
What the order is, in one paragraph
It directs US federal agencies to say Super Intelligence and SI in their own non-statutory materials, and it defines SI as the technologies already covered by the statutory definition of artificial intelligence. Same scope, new word. It does not amend regulation, and it has no effect outside the US federal executive branch — Europe, the UK and every standards body still say artificial intelligence. A separate industry accord was signed the same day; it is voluntary.
Detail in what the rename changes and what SI actually means.
Where it lands across the business
Research. Nothing. The models your computational chemists use do not care what the government calls them. Publication language follows journals and ICH conventions, not executive orders.
Clinical. Little, except in submissions and correspondence with FDA, where matching the agency's vocabulary is ordinary practice. Protocols and trial master files follow ICH, which still says artificial intelligence.
Manufacturing and quality. Nothing of substance. The obligations around validated systems are untouched, as covered in what has not changed.
Commercial and partnering. This is where it bites. Pitch decks, RFPs, vendor comparisons and investor materials will switch quickly, because the people writing them are rewarded for sounding current. Expect "SI-enabled" on slides long before any product changes.
Procurement. Watch for requirements written as "must be SI-powered". That is a specification that cannot be evaluated, and it invites exactly the relabelled products described in SI washing.
The one thing with real consequences
The order commissions a federal definition of Super Intelligence that has not yet been written. Today SI borrows the existing statutory definition of AI, so scope is unchanged. A future definition could narrow or widen what counts.
That matters to this industry more than most, because scope determines which systems any future requirement reaches. A definition that pulls in ordinary statistical models would catch a great deal of what pharma already runs — process analytics, stability prediction, deviation trending. One that applies only to frontier models would catch almost none of it.
It is the only part of this story worth putting on a regulatory watch list. The word is not.
What a sensible company does this quarter
- Nothing urgent. No document project, no rebrand, no policy rewrite. One sentence in your AI policy noting the terms are equivalent covers it — see do you need to rename AI in your SOPs.
- Add SI to regulatory monitoring keywords, or you will quietly stop catching new FDA material.
- Brief commercial and procurement teams that SI and AI mean the same thing, so nobody buys a relabel or writes an unevaluable requirement.
- Keep your own language steady. In an industry that buys on trust, being the company that did not redraw its slides the week the word changed is worth more than being first.
Where AI genuinely is working across this sector is a separate and more useful question — see AI in pharma 2026 and GxP AI.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.